![Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite](https://aglaia-oncology.com/media/uploads/en/news/og/Logo_Aglaia_Oncology_Funds.jpg?_=1581598417)
Aglaia Oncology Funds and Sinzer - Grant Thornton Launch Dedicated Life Sciences Impact Measuring and Reporting Suite
![New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies | AdBio New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies | AdBio](https://adbio.partners/wp-content/uploads/2021/11/Groupe-281@2x-886x675.png)
New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies | AdBio
![New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies | Institut Curie New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies | Institut Curie](https://institut-curie.org/sites/default/files/styles/rectangle_grand_crop/public/medias/images/2021-09/VISUEL%20TTO_.png?h=49d301e8&itok=lFSTGR8F)
New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies | Institut Curie
![Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A | Business Wire Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A | Business Wire](https://mms.businesswire.com/media/20211007005056/en/824834/23/Logo_Sapreme_5k_x_4k_transparent.jpg)
Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A | Business Wire
![Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology | AdBio Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology | AdBio](https://adbio.partners/wp-content/uploads/2021/11/Groupe-282@2x-886x675.png)
Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology | AdBio
![Aglaia Therapeutics: a new start-up from Institut Curie & Gustave Roussy raises €4M to fight resistance to targeted therapies | Technology Transfer Office Aglaia Therapeutics: a new start-up from Institut Curie & Gustave Roussy raises €4M to fight resistance to targeted therapies | Technology Transfer Office](https://techtransfer.institut-curie.org/sites/techtransfer/files/styles/petit_echelle/public/media-thumbnails/2021/09/1084.png?itok=NBxC1e2d)